Stéphane Noble
Long-Term Effect of Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents in Patients With Small Vessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the BIOSCIENCE Randomized Trial
Iglesias J, Windecker S, Jüni P, Häner J, Cuculi F, Kaiser C, Weilenmann D, Cook S, Moarof I, Muller O, Noble S, Tüller D, Roffi M, Heg D, Pilgrim T. Long-Term Effect of Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents in Patients With Small Vessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the BIOSCIENCE Randomized Trial. Circ Cardiovasc Interv 2019; 12:e008024.
06.08.2019Long-Term Effect of Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents in Patients With Small Vessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the BIOSCIENCE Randomized Trial
06.08.2019Circ Cardiovasc Interv 2019; 12:e008024
Iglesias Juan F, Windecker Stephan, Jüni Peter, Häner Jonas, Cuculi Florim, Kaiser Christoph, Weilenmann Daniel, Cook Stéphane, Moarof Igal, Muller Olivier, Noble Stéphane, Tüller David, Roffi Marco, Heg Dik, Pilgrim Thomas
Circadian dependence of manual thrombus aspiration benefit in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
Fournier S, Iglesias J, Eeckhout E, Windecker S, Masci P, Degrauwe S, Zuffi A, Fesselet R, Noble S, Cook S, Erne P, Radovanovic D, Rickli H, Eberli F, Pilgrim T, Roffi M, Benedetto U, Muller O, on behalf on the AMIS Plus Investigators. Circadian dependence of manual thrombus aspiration benefit in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Clin Res Cardiol 2017
08.12.2017Circadian dependence of manual thrombus aspiration benefit in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
08.12.2017Clin Res Cardiol 2017
Fournier Stephane, Iglesias Juan F, Eeckhout Eric, Windecker Stephan, Masci PierGiorgio, Degrauwe Sophie, Zuffi Andrea, Fesselet Rachel, Noble Stéphane, Cook Stéphane, Erne Paul, Radovanovic Dragana, Rickli Hans, Eberli Franz R, Pilgrim Thomas, Roffi Marco, Benedetto Umberto, Muller Olivier, on behalf on the AMIS Plus Investigators
Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial
Pilgrim T, Jüni P, Wenaweser P, Eberli F, Noble S, Moschovitis A, Fahrni T, Jamshidi P, Kaiser C, Weilenmann D, Cook S, Vuilliomenet A, Muller O, Tüller D, Roffi M, Heg D, Windecker S. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial. Lancet 2014; 384:2111-22.
01.09.2014Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial
01.09.2014Lancet 2014; 384:2111-22
Pilgrim Thomas, Jüni Peter, Wenaweser Peter, Eberli Franz R, Noble Stéphane, Moschovitis Aris, Fahrni Therese, Jamshidi Peiman, Kaiser Christoph, Weilenmann Daniel, Cook Stéphane, Vuilliomenet André, Muller Olivier, Tüller David, Roffi Marco, Heg Dik, Windecker Stephan